Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation

• Published in: Journal of advanced research Vol. 33; pp. 241 - 251
• Main Authors: Li, Heng, Zhang, Xianglei, Xiang, Caigui, Feng, Chunlan, Fan, Chen, Liu, Moting, Lu, Huimin, Su, Haixia, Zhou, Yu, Qi, Qing, Xu, Yechun, Tang, Wei
• Format: Journal Article
• Language: English
• Published: Egypt Elsevier B.V 01.11.2021; Elsevier
• Subjects: Animals; Arctigenin; Cyclic Nucleotide Phosphodiesterases, Type 4; Furans; Humans; Inflammation; Inflammation - chemically induced; Inflammation - drug therapy; Leukocytes, Mononuclear; Lignans - pharmacology; Lignans - therapeutic use; Mice; Original; PDE4; Psoriasis; Arctigenin; Inflammation; Psoriasis; PDE4
• ISSN: 2090-1232; 2090-1224
• DOI: 10.1016/j.jare.2021.02.006

Arctigenin, derived from Arctium lappa L., has multiple pharmacological activities, including immunoregulatory, anti-diabetic, anti-tumor, and neuroprotective effects. Nevertheless, the potential therapeutic target of arctigenin in modulating inflammation remains undefined. In the present study, we identified that arctigenin was a phosphodiesterase-4 (PDE4) selective inhibitor for the first time. Further investigations were performed to fully uncover the effects and mechanism of arctigenin on experimental murine psoriasis model. Crystal structure determination, PDEs enzyme assay, and isothermal titration calorimetry were included to illustrate the binding specialty, inhibitory effects, and selectivity of arctigenin on PDE4D. The anti-inflammatory effects were conducted in LPS-activated human peripheral blood mononuclear cells (PBMCs) and RAW264.7 cells. Imiquimod-induced murine psoriasis was performed to uncover the therapeutic effects and mechanism of arctigenin in vivo. Arctigenin could bind to the catalytic domain of PDE4D via formation of hydrogen bonds as well as π-π stacking interactions between the dibenzyl butyrolactone of arctigenin and several residues of PDE4D. Accordingly, arctigenin showed prominent anti-inflammation in human PBMCs and murine RAW264.7 cells. PDE4 inhibition by arctigenin resulted in elevation of intracellular cyclic adenosine monophosphate (cAMP) and phosphorylation of cAMP-response element binding protein (CREB), which were largely blocked through intervention of protein kinase A (PKA) activity by H89 treatment or reduction of protein expression by siRNA transfection. Moreover, we first identified that a topical application of arctigenin ameliorated experimental psoriatic manifestations in imiquimod-induced murine psoriasis model by decreasing adhesion and chemotaxis of several inflammatory cells. Further proteomics analysis revealed that arctigenin could rectify the immune dysfunction and hyperactivation of keratinocytes in the inflamed skin microenvironments, which might be largely related to the expression of Keratins. The research provided credible clew that inhibition of PDE4 by arctigenin might function as the potential therapeutic approach for the treatment of psoriasis.